Rekombinanter IL12B (Briakinumab Biosimilar) Antikörper

Produktnummer ABIN7795102

Der Maus Monoklonal anti-IL12B (Briakinumab Biosimilar) Antikörper (ABIN7795102) detektiert spezifisch IL12B (Briakinumab Biosimilar) in FACS und in vivo. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Rekombinanter IL12B (Briakinumab Biosimilar) Antikörper (ABIN7795102)

Target: IL12B (Briakinumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser IL12B (Briakinumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-IL12B (Briakinumab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Briakinumab Biosimilar, IL-12 / IL-23 Monoclonal Antibody

Produktmerkmale: What is Briakinumab Biosimilar research grade? Briakinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn's Disease and other autoimmune and inflammatory disorders. Briakinumab Biosimilar uses the same protein sequences as the therapeutic antibody briakinumab.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human IL-12 / IL-23

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu IL12B (Briakinumab Biosimilar)

Target: IL12B (Briakinumab Biosimilar)

Andere Bezeichnung: Briakinumab Biosimilar

Substanzklasse: Biosimilar